Nebivolol lowers blood pressure and increases weight loss in patients with hypertension and diabetes in regard to age

Journal of Cardiovascular Pharmacology

Volumn 56, Issue 3, 2010, Pages 275-281

  Ladage, Dennis ^a,b   Reidenbach, Christian ^a,b   Rieckeheer, Eva ^a   Graf, Christine ^a   Schwinger, Robert H G ^c   Brixius, Klara ^a  

^a GERMAN SPORT UNIVERSITY COLOGNE   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c Clinic II of Internal Medicine and Cardiology   (Germany)

Author keywords

age; diabetes; gender; hypertension; nebivolol

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NEBIVOLOL; ORAL ANTIDIABETIC AGENT;

ADD ON THERAPY; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD PRESSURE REGULATION; BODY MASS; BODY WEIGHT; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; WEIGHT REDUCTION;

ADRENERGIC BETA-ANTAGONISTS; AGE FACTORS; AGED; BENZOPYRANS; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; ETHANOLAMINES; FEMALE; HEART RATE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; SEX FACTORS; WEIGHT LOSS;

EID: 77957559010     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181eb4ff2     Document Type: Article

References (28)

1. Wild S, Roglic G, Green A., et al Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27: 1047-1053.
2. Anonymous tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317:703-713.
3. Stamler J, Vaccaro O, Neaton J.D., et al Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care. 1993;16:434-444.
4. Anonymous Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens. 1993;11:309-317.
5. Williams B, Poulter NR, Brown M.J., et al Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens. 2004;18: 139-185.
6. Chobanian AV, Bakris GL, Black H.R., et al Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252.
7. Brixius K, Bundkirchen A, Bolck B., et al Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium. Br J Pharmacol. 2001;133:1330-1338.
8. Ladage D, Brixius K, Hoyer H., et al Mechanisms underlying nebivolol-induced endothelial nitric oxide synthase activation in human umbilical vein endothelial cells. Clin Exp Pharmacol Physiol. 2006;33:720-724.
9. Dessy C, Saliez J, Ghisdal P., et al Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol. Circulation. 2005;112:1198-1205.
10. Von Fallois J., Faulhaber HD [Nebivolol, a third generation beta blocker: the modern treatment of hypertension. Results of a multicentric observational study]. Fortschr Med Orig. 2000;118(SUPPL. 2):77-82.
11. Ren J, Ceylan-Isik AF. Diabetic cardiomyopathy: do women differ from men? Endocrine. 2004;25:73-83.
12. Rascher W. [Measuring blood pressure in children. Instructions for general practice. Part 1: practical procedure-blood pressure cuffs]. Fortschr Med. 1994;112:296-297.
13. Caballero AE. Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease. Obes Res. 2003;11:1278-1289.
14. Coats AJ. Beta-adrenoceptor antagonists in elderly patients with chronic heart failure: therapeutic potential of third-generation agents. Drugs Aging. 2006;23:93-99.
15. Martins D, Nelson K, Pan D., et al The effect of gender on age-related blood pressure changes and the prevalence of isolated systolic hypertension among older adults: data from NHANES III. J Gend Specif Med. 2001;4:10-13, 20.
16. Reckelhoff JF. Gender differences in the regulation of blood pressure. Hypertension. 2001;37:1199-1208.
17. Khalil RA. Sex hormones as potential modulators of vascular function in hypertension. Hypertension. 2005;46:249-254.
18. Chen DB, Bird IM, Zheng J, et al Membrane estrogen receptor-dependent extracellular signal-regulated kinase pathway mediates acute activation of endothelial nitric oxide synthase by estrogen in uterine artery endothelial cells. Endocrinology. 2004;145:113-125.
19. Garban HJ, Buga GM, Ignarro LJ Estrogen receptor-mediated vascular responsiveness to nebivolol: a novel endothelium-related mechanism of therapeutic vasorelaxation. J Cardiovasc Pharmacol. 2004;43:638-644.
20. Giugliano D, Marfella R, Acampora R., et al Effects of perindopril and carvedilol on endothelium-dependent vascular functions in patients with diabetes and hypertension. Diabetes Care. 1998;21:631-636.
21. Andersson D, Wahrenberg H, Lofgren P. Beta3-adrenoceptor function and long-term changes in body weight. Int J Obes (Lond). 2009;33: 662-668.
22. Ladage D, Reidenbach C, Lichtenthal A., et al [Third generation beta-blockers: current state of research on vasodilating beta-blockers]. Wien Med Wochenschr. 2009;159:211-218.
23. Zhou X, Ma L, Habibi J., et al Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the zucker obese rat. Hypertension. 2010;55:880-888.
24. Celik T, Iyisoy A, Kursaklioglu H., et al Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens. 2006; 24:591-596.
25. Germino FW. Efficacy and tolerability of nebivolol monotherapy by baseline systolic blood pressure: a retrospective analysis of pooled data from two multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging studies in patients with mild to moderate essential hypertension. Clin Ther. 2009;31:1946-1956.
26. Van Bortel L.M., Bulpitt CJ, Fici F. Quality of life and antihyper-tensive effect with nebivolol and losartan. Am J Hypertens. 2005;18: 1060-1066.
27. Schmidt AC, Graf C, Brixius K., et al Blood pressure-lowering effect of nebivolol in hypertensive patients with type 2 diabetes mellitus: the YESTONO study. Clin Drug Investig. 2007;27:841-849.
28. Van Nueten L., Lacourciere Y, Vyssoulis G., et al Nebivolol versus nifedipine in the treatment of essential hypertension: a double-blind, randomized, comparative trial. Am J Ther. 1998;5:237-243.